PPAR-γ agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis

Pulmonary fibrosis is characterized by alterations in fibroblast phenotypes resulting in excessive extracellular matrix accumulation and anatomic remodeling. Current therapies for this condition ar...

[1]  Julian Taranda,et al.  Dilated cardiomyopathy in Erb-b4-deficient ventricular muscle. , 2005, American journal of physiology. Heart and circulatory physiology.

[2]  B. Spiegelman,et al.  PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. , 1997, Genes & development.

[3]  S. Fiorucci,et al.  PPARs and other nuclear receptors in inflammation. , 2006, Current opinion in pharmacology.

[4]  Biao Hu,et al.  CCAAT/Enhancer-Binding Protein β Isoforms and the Regulation of α-Smooth Muscle Actin Gene Expression by IL-1β1 , 2004, The Journal of Immunology.

[5]  T. Willson,et al.  Peroxisome Proliferator-activated Receptors and Hepatic Stellate Cell Activation* , 2000, The Journal of Biological Chemistry.

[6]  P. Watkins,et al.  Hepatic dysfunction associated with troglitazone. , 1998, The New England journal of medicine.

[7]  J. Seo,et al.  Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. , 2005, Chest.

[8]  M. Koukourakis,et al.  Radiation pneumonitis and fibrosis: mechanisms underlying its pathogenesis and implications for future research. , 2006, International journal of radiation oncology, biology, physics.

[9]  R. Routh,et al.  Troglitazone suppresses the secretion of type I collagen by mesangial cells in vitro. , 2002, Kidney international.

[10]  S. Kulp,et al.  Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma. , 2005, Cancer research.

[11]  N. Enomoto,et al.  Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride. , 2002, Biochemical and biophysical research communications.

[12]  D. Dombrowicz,et al.  Peroxisome proliferator-activated receptor gamma is expressed in airways and inhibits features of airway remodeling in a mouse asthma model. , 2004, The Journal of allergy and clinical immunology.

[13]  S. Bernstein,et al.  CD40 Engagement Prevents Peroxisome Proliferator-Activated Receptor γ Agonist-Induced Apoptosis of B Lymphocytes and B Lymphoma Cells by an NF-κB-Dependent Mechanism1 , 2005, The Journal of Immunology.

[14]  M. Kramer,et al.  Concomitant upper-lobe bullous emphysema, lower-lobe interstitial fibrosis and pulmonary hypertension in heavy smokers: report of eight cases and review of the literature. , 2005, Respiratory medicine.

[15]  F. Martinez,et al.  Mechanisms of pulmonary fibrosis. , 2004, Annual review of medicine.

[16]  S. Phan,et al.  Molecular mechanisms of and possible treatment strategies for idiopathic pulmonary fibrosis. , 2005, Current pharmaceutical design.

[17]  P. Cherin,et al.  [Pleuropulmonary manifestations of systemic lupus erythematosus]. , 1991, La Revue de medecine interne.

[18]  R. DeFronzo.  Pharmacologic Therapy for Type 2 Diabetes Mellitus , 1999, Annals of Internal Medicine.

[19]  T. Willson,et al.  Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase , 1999, Nature.

[20]  B. Willis,et al.  Epithelial origin of myofibroblasts during fibrosis in the lung. , 2006, Proceedings of the American Thoracic Society.

[21]  J. Roman,et al.  Rosiglitazone suppresses human lung carcinoma cell growth through PPARγ-dependent and PPARγ-independent signal pathways , 2006, Molecular Cancer Therapeutics.

[22]  S. Kudoh,et al.  Occupational and environmental factors and idiopathic pulmonary fibrosis in Japan. , 2005, The Annals of occupational hygiene.

[23]  J. Jimenez-Heffernan,et al.  Myofibroblastic Differentiation in Simple Peritoneal Sclerosis , 2005, The International journal of artificial organs.

[24]  A. Ghosh,et al.  Disruption of transforming growth factor β signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator–activated receptor γ , 2004 .

[25]  V. Keshamouni,et al.  Deactivation of murine alveolar macrophages by peroxisome proliferator-activated receptor-gamma ligands. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[26]  Youming Peng,et al.  Troglitazone inhibits synthesis of transforming growth factor‐β1 and reduces matrix production in human peritoneal mesothelial cells , 2006, Nephrology.

[27]  G. Raghu,et al.  Effects of platelet-derived growth factor isoforms on human lung fibroblast proliferation and procollagen gene expression. , 1993, Experimental lung research.

[28]  T. Kurtz,et al.  Design and Synthesis of the First Generation of Dithiolane Thiazolidinedione- and Phenylacetic Acid-Based PPARγ Agonists , 2006 .

[29]  V. Keshamouni,et al.  Peroxisome Proliferator-activated Receptor-γ as a Regulator of Lung Inflammation and Repair , 2005 .

[30]  A. Masamune,et al.  Ligands of Peroxisome Proliferator-activated Receptor-γ Block Activation of Pancreatic Stellate Cells* , 2002, The Journal of Biological Chemistry.

[31]  W. Wahli,et al.  Involvement of PPAR nuclear receptors in tissue injury and wound repair. , 2006, The Journal of clinical investigation.

[32]  B. P. Kota,et al.  The pathophysiological function of peroxisome proliferator-activated receptor-γ in lung-related diseases , 2005, Respiratory research.

[33]  C. Agostini,et al.  Chemokine/cytokine cocktail in idiopathic pulmonary fibrosis. , 2006, Proceedings of the American Thoracic Society.

[34]  K. Csiszȧr,et al.  Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis , 2005, Arthritis research & therapy.

[35]  D. Warburton,et al.  The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? , 2008, The international journal of biochemistry & cell biology.

[36]  V. Keshamouni,et al.  Peroxisome proliferator-activated receptor-γ activation inhibits tumor progression in non-small-cell lung cancer , 2004, Oncogene.

[37]  K. Flanders,et al.  Effect of overexpression of pparγ on the healing process of comeal alkali burn in mice , 2007 .

[38]  Tomomi Ikeda,et al.  Clinical features and genetic analysis of surfactant protein C in adult‐onset familial interstitial pneumonia , 2006, Respirology.

[39]  S. Fischer,et al.  Troglitazone inhibits cyclin D1 expression and cell cycling independently of PPARgamma in normal mouse skin keratinocytes. , 2004, The Journal of investigative dermatology.

[40]  S. Efrati,et al.  Apoptosis and proliferation of cultured mesangial cells isolated from kidneys of rosiglitazone-treated pregnant diabetic rats. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[41]  P. Poleni,et al.  Agonists of peroxisome proliferators-activated receptors (PPAR) α, β/δ or γ reduce transforming growth factor (TGF)-β-induced proteoglycans' production in chondrocytes , 2007 .

[42]  M. Layne,et al.  Telomerase, myofibroblasts, and pulmonary fibrosis. , 2006, American journal of respiratory cell and molecular biology.

[43]  W. Roesler,et al.  Unique ability of troglitazone to up-regulate peroxisome proliferator-activated receptor-gamma expression in hepatocytes. , 2002, The Journal of pharmacology and experimental therapeutics.

[44]  R. Agarwal,et al.  Autoimmunity and interstitial lung disease , 2005, Current opinion in pulmonary medicine.

[45]  O. Sharma,et al.  Epstein-Barr-virus-induced interstitial lung disease , 2005, Current opinion in pulmonary medicine.

[46]  P. Gibson,et al.  Proteomic study of plasma proteins in pregnant women with asthma , 2006, Respirology.

[47]  R. Strieter,et al.  Mechanisms and mediators of pulmonary fibrosis. , 2005, Critical reviews in immunology.

[48]  Hyun-Joung Lim,et al.  Troglitazone inhibits endothelial cell proliferation through suppression of casein kinase 2 activity. , 2006, Biochemical and biophysical research communications.

[49]  N. Siafakas,et al.  Pathogenetic pathways and novel pharmacotherapeutic targets in idiopathic pulmonary fibrosis. , 2007, Pulmonary pharmacology & therapeutics.

[50]  F. Martinez,et al.  Idiopathic pulmonary fibrosis: emerging concepts on pharmacotherapy , 2004, Expert opinion on pharmacotherapy.

[51]  Jongkyeong Chung,et al.  Troglitazone acutely inhibits protein synthesis in endothelial cells via a novel mechanism involving protein phosphatase 2A-dependent p70 S6 kinase inhibition. , 2006, American journal of physiology. Cell physiology.

[52]  V. Mehta.  Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary function, prediction, and prevention. , 2005, International journal of radiation oncology, biology, physics.

[53]  J. Berger,et al.  The mechanisms of action of PPARs. , 2002, Annual review of medicine.

[54]  T. Thatcher,et al.  PPARγ agonists inhibit TGF-β induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis , 2005 .

[55]  K. Flanders,et al.  Effect of overexpression of PPARgamma on the healing process of corneal alkali burn in mice. , 2007, American journal of physiology. Cell physiology.

[56]  E. Mazzon,et al.  Effect of rosiglitazone and 15-deoxy-Δ12,14-prostaglandin J2 on bleomycin-induced lung injury , 2005, European Respiratory Journal.

[57]  T. Sugimoto,et al.  Peroxisome proliferator-activated receptor-γ ligands inhibit TGF-β1-induced fibronectin expression in glomerular mesangial cells , 2004 .

[58]  G. Hunninghake,et al.  Idiopathic pulmonary fibrosis. , 2001, The New England journal of medicine.

[59]  T. van der Poll,et al.  Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice. , 2005, The American journal of pathology.

[60]  E. Schleicher,et al.  c-Fos-driven transcriptional activation of transforming growth factor beta-1: inhibition of high glucose-induced promoter activity by thiazolidinediones. , 2003, Biochemical and biophysical research communications.

[61]  R. Day,et al.  Myofibroblast Differentiation by Transforming Growth Factor-β1 Is Dependent on Cell Adhesion and Integrin Signaling via Focal Adhesion Kinase* , 2003, Journal of Biological Chemistry.

[62]  M. Rugge,et al.  A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. , 2004, Gastroenterology.

[63]  I. Lu,et al.  Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities. , 2006, Journal of medicinal chemistry.

[64]  G. Raghu,et al.  Differential proliferation of fibroblasts cultured from normal and fibrotic human lungs. , 1988, The American review of respiratory disease.

[65]  Sandor Vajda,et al.  Exploring the binding site structure of the PPAR gamma ligand-binding domain by computational solvent mapping. , 2005, Biochemistry.

[66]  A. Diehl,et al.  PPARγ Agonists Prevent TGFβ1/Smad3-Signaling in Human Hepatic Stellate Cells , 2006 .

[67]  A. August,et al.  Nutrients, nuclear receptors, inflammation, immunity lipids, PPAR, and allergic asthma. , 2006, The Journal of nutrition.

[68]  D. Crabb,et al.  Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. , 2002, Gastroenterology.

[69]  Danielle G. Lemay,et al.  Genome-wide identification of peroxisome proliferator response elements using integrated computational genomics s⃞ Published, JLR Papers in Press, April 3, 2006. , 2006, Journal of Lipid Research.

[70]  S. Phan.  The myofibroblast in pulmonary fibrosis. , 2002, Chest.

[71]  T. Harris,et al.  PPARγ ligands, 15‐deoxy‐Δ12,14‐prostaglandin J2 and rosiglitazone regulate human cultured airway smooth muscle proliferation through different mechanisms , 2004 .

[72]  C. Pollock,et al.  PPARgamma agonists exert antifibrotic effects in renal tubular cells exposed to high glucose. , 2005, American journal of physiology. Renal physiology.

[73]  G. Striker,et al.  Upregulation of type I collagen by TGF-β in mesangial cells is blocked by PPARγ activation , 2002 .

[74]  N. Brunskill,et al.  Differential effects of peroxisome proliferator activated receptor-γ (PPARγ) ligands in proximal tubular cells: Thiazolidinediones are partial PPARγ agonists , 2004 .